drugset / Trial / NCT00003023
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
Phase 1
Completed
24 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody A1G4 with BCG may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody A1G4 plus BCG in treating patients with cancer.
Timeline
- Start
- 1997-03
- Primary completion
- 2005-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | A1G4 | Monoclonal antibody | — | Intravenous |
| Background | Bacillus Calmette Guerin | Vaccine | — | Intravenous |